Pentavalent rotavirus vaccine (RotaTeq ® ) in the prevention of rotavirus gastroenteritis: a profile of its use in the EU
AbstractRotaTeq® is a three-dose, pentavalent, human-bovine reassortment vaccine, indicated for the prevention of rotavirus gastroenteritis (RVGE) in infants aged 6 –32 weeks in the EU. The vaccine solution is given orally and can be administered with a number of common childhood vaccines. In the pivotal REST study, RotaTeq® showed high protective efficacy with respect to reductions in the RVGE incidence and associated hospitalizations or emergency department visits. The effectiveness and impact of the vaccine against RVGE-related healthcare use were demonstrated in several real-world studies. RotaTeq® was generally well tolerated, with no or minimal risk of intussusception.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research
More News: Drugs & Pharmacology | Emergency Medicine | Gastroenteritis | Gastroenterology | Intussusception | Rotavirus | Rotavirus Vaccine | Study | Vaccines